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ABSTRACT
Implementation trials often involve clustering via risk networks, where only some
participants directly received the intervention. The individual effect is that among
directly treated persons beyond being in an intervention network; the disseminated
effect is that among persons engaged with those directly treated. We employ a
causal inference framework and discuss assumptions and estimators for individual
and disseminated effects and apply them to HIV Prevention Trials Network 037. HIV
Prevention Trials Network 037 was a Phase III, network-level, randomized
controlled HIV prevention trial conducted in the US and Thailand from 2002 to 2006
that recruited persons who injected drugs, who received either intervention or
control, and their risk network members, who received no direct intervention.
Combining individual and disseminated, a 35% composite rate reduction was
observed in the adjusted model (95% confidence interval = 0.47, 0.90). Methodology
is now available to estimate the full set of these effects enhancing knowledge gained
from network-randomized trials. Although the overall effect gains validity from
network randomization, we show that it will, in general, be less than the composite
effect. Additionally, if only index participants benefit from the intervention, as the
network size increases, the overall effect tends to the null, an unfortunate and
misleading conclusion.
Keywords: Causal inference; Cluster-randomized trials; Disseminated/Indirect
effects; Drug use/abuse; HIV/AIDS; Implementation Science; Individual/Direct
effects; Interference
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Implementation science studies how best to translate and scale-up research
evidence into practice. These studies often involve a natural clustering by social
network, facility or community. In such network-randomized trials, only some
members of networks randomized to the intervention directly receive the
intervention. Individual and disseminated effects can be targets of inference. The
disseminated or indirect effect is the impact of the intervention on the network
members who were not directly exposed in the intervention networks. The
individual or direct effect is the impact of the intervention on those who directly
received the intervention, the index participants in intervention networks, beyond
being an intervention network member. The composite effect is the effect of the
intervention on index participants compared to network control members; that is,
the maximal attainable benefit of the intervention. For example, a health care
professional may educate an index participant, also known as the ego, who then in
turn may educate or otherwise influence members of his or her risk network, also
known as the alter-egos, to modify their risky practices. In this setting, there is
interest in the intervention effect on those who were directly educated as well as
those sharing risk networks with the index.
The terms individual and disseminated are used in this paper to avoid
confusion with these terms used in the mediation literature, where the direct and
indirect effects are terms used to describe parameters addressing different scientific
questions (1). We present a summary of the vernacular from relevant literature on
the present topic and provide our recommended terms in Table 1. Compared to
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previous terminology, our terms are more agnostic to the relative magnitudes and
desirability of dissemination.
In causal inference methodology, a fundamental assumption of much work is
the stable unit treatment value assumption, that is, SUTVA (2), which includes an
assumption of no dissemination, or interference, between individuals. No
dissemination requires that the potential outcomes of one individual are unaffected
by the intervention assignment of other individuals. In this paper, the primary
research interest is precisely in relaxing the no dissemination assumption of the
stable unit treatment value assumption and quantifying disseminated effects.
Earlier work on methods for assessing dissemination assumed two-stage
randomization, where networks were first randomized to an intervention allocation
strategy and, then, within a network, individuals were randomized according to
their network’s allocation strategy (3, 4). Estimators of individual and disseminated
effects were motivated by vaccine studies, where herd immunity is a good example
of a disseminated effect (5, 6). Permutation-based variance estimators were
developed for these doubly-randomized designs (4). When a study is not doubly
randomized, these estimators of individual and disseminated effects are no longer
valid because of the potential for bias due to confounding at either the network-,
individual- level or both. Tchetgen Tchetgen and VanderWeele (7) proposed inverse
probability weighted estimators of individual and disseminated effects for studies
where randomization is not required at the individual or group level. This approach
was applied to an individually-randomized study of cholera vaccine, where
individuals were clustered by groups of households. (8). This approach was then
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applied to a study design with more than one index member and unequal treatment
probabilities in the second stage (9).
Using multivariable outcome models rather than inverse probability
weighted models, we develop alternative estimators of individual, disseminated and
composite causal effects for a setting with randomization only at the network level
and one index per network, a study design frequently utilized in drug abuse and
addiction research (10-12), and provide methods for asymptotic inference. We
discuss the causal inference framework and assumptions for this setting. We prove
some general results of interest in this setting that demonstrate the utility of the
methods proposed. We apply these methods to a network-randomized trial in the
HIV Prevention Trials Network (HPTN)(13-15) to obtain estimates of the individual,
disseminated, composite, and overall intervention effects. Lastly, we discuss some
limitations of this approach and identify future methodological directions for causal
inference in network-randomized studies.
METHODS
Assumptions and Notation
The sufficient conditions for valid estimation of causal effects have been
previously described (16) . We assume no dissemination between networks.
Because the networks are randomized to the intervention, on average,
exchangeability at the network level holds. Networks randomized to the
intervention will be, on average, comparable to networks randomized to the control.
There is an additional exchangeability assumption that allows for valid estimation of
all the parameters of interest in this setting. Within each network, conditional on a
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set of measured covariates, the potential outcomes of the voluntary index
participants and non-index network members are the same as, on average, that
would be expected if any other network member volunteered to be the index,
whether the network was randomized to the intervention or not. We call this
“conditional index exchangeability”.
Let 𝐾 be the total number of networks, 𝑘 = 1, … , 𝐾, with 𝑖 = 1, … , 𝑛𝑘
participants in network 𝑘, where each participant 𝑖 has 𝑗 = 1, … , 𝑚𝑘𝑖 visits and
∑𝐾
𝑘=1 𝑛𝑘 = 𝑁 is the total sample size of the study. Let 𝒁𝑘𝑖 be a vector of measured
baseline covariates for participant 𝑖 in network 𝑘. Define 𝑌𝑘𝑖𝑗 as the outcome for the
𝑖 th participant in the 𝑘 th network at the 𝑗th visit. Let 𝑋𝑘 be the network-level
intervention in network 𝑘 assigned at the start of the trial and define an indicator
𝑅𝑘𝑖 for the individual-level index status, where 𝑅𝑘𝑖 = 1 if participant 𝑖 in network 𝑘
is an index and 𝑅𝑘𝑖 = 0 otherwise. For example, investigators assign HIV risk
networks either to train their index member to be peer educator or standard of care
with HIV counseling and testing. In network 𝑘, we have an 𝑛𝑘 -vector of observed
index status indicators 𝑹𝑘 = (𝑅𝑘1 , 𝑅𝑘2 , … , 𝑅𝑘𝑛𝑘 ), constrained in this paper
𝑛

𝑘
to ∑𝑖=1
𝑅𝑘𝑖 = 1 and 𝑛𝑘 -vectors of baseline covariates 𝒁𝑘 = (𝑍𝑘1, 𝑍𝑘2 , … , 𝑍𝑘𝑛𝑘 ). Each

participant has potential outcomes 𝒀𝑘𝑖𝑗 (𝒓, 𝑥), which correspond to the 2 × 𝑛𝑘 vector
of potential outcomes for individual 𝑖 in network 𝑘 at time 𝑗 under the index status
indicator vector 𝑹𝑘 = 𝒓 and intervention assignment 𝑋𝑘 = 𝑥. Because an
individual’s potential outcomes depend on the network-level intervention,
dissemination is possible in this setting. A contrast between any two of these
potential outcomes is a measure of a causal effect. For example, a representation of
Network-Randomized Studies with Dissemination
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the individual causal effect in an intervention network where the second participant
was the index compared to when the last participant was the index is
𝐸{𝒀𝑘𝑖𝑗 [(0,1, … 0), 1]} − 𝐸{𝒀𝑘𝑖𝑗 [(0,1, … 1), 1]}.
Because the number of index members in network 𝑘 is fixed to 1 by design,
𝑛
there are 𝐽𝑘 = ( 𝑘 ) = 𝑛𝑘 possible configurations of index participants in each
1
network 𝑘. In general, each network member has 2 × 𝑛𝑘 potential outcomes with 𝑛𝑘
corresponding to intervention and 𝑛𝑘 corresponding to control. With these many
potential outcomes within networks, it is difficult to choose the causal effects of
interest. Conditional on baseline covariates, we assume that there is exchangeability
between the 2 × 𝑛𝑘 possible configurations when there is one index participant in
network 𝑘; that is, 𝑌𝑘𝑖𝑗 (𝒓, 𝑥) ⊥ 𝑹𝑘 | 𝒁𝑘 . Baseline covariates are sufficient to control
for confounding of the effect of self-selected index status on the outcome. Because
there is only one index per network, we can validly denote the potential outcomes
by 𝑅𝑘𝑖 = 𝑟 and 𝑋𝑘 = 𝑥. Under these circumstances, the number of potential
outcomes for each participant, 𝑌𝑘𝑖𝑗 (𝑟, 𝑥), is reduced to four; that is, two for each of
the two possible network-level intervention assignments, 𝑌𝑘𝑖𝑗 (1,1),
𝑌𝑘𝑖𝑗 (1,0), 𝑌𝑘𝑖𝑗 (0,1), and 𝑌𝑘𝑖𝑗 (0,0). For example, let 𝑌𝑘𝑖𝑗 (1,1) be the potential outcome
of participant 𝑖 at visit 𝑗 in network 𝑘, if, possibly contrary to fact, this participant
was an index member in a network randomized to the intervention.
Causal Framework and Estimands
The individual effect is defined as the effect of the intervention among index
members in intervention networks beyond being in an intervention network (Figure
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1), that is, Risk/Rate DifferenceI (𝑅𝐷𝐼 ) = 𝐸[𝑌𝑘𝑖𝑗 (1,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,1)]. The
disseminated effect is defined as the intervention effect among the non-index
network members, that is, 𝑅𝐷𝐷 = 𝐸[𝑌𝑘𝑖𝑗 (0,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,0)]. Composite and
overall effects combine the individual and disseminated effects in two different
ways. The composite effect is the sum of the disseminated and individual effects,
that is 𝑅𝐷𝐶𝑜𝑚𝑝 = 𝐸[𝑌𝑘𝑖𝑗 (1,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,1)] + {𝐸[𝑌𝑘𝑖𝑗 (0,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,0)]} =
𝐸[𝑌𝑘𝑖𝑗 (1,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,0)]. The composite effect is the maximum possible effect of
the intervention; that is, the effect of being an index member in an intervention
network compared to a network member in a control network.
The overall effect is the average effect among all intervention network
members compared to all control network members. In Web Appendix 1, we derive
the parametric relationship between the individual and disseminated effects and the
overall effect, and show that when network sizes vary, 𝑅𝐷𝑂𝑣𝑒𝑟𝑎𝑙𝑙 = 𝐸[𝑌𝑘𝑖𝑗 (∙, 1)] −
𝐾

𝐸[𝑌𝑘𝑖𝑗 (∙, 0)] = 𝑅𝐷𝐷 + 𝑅𝐷𝐼 × 𝐸𝑅 [𝑅𝑘𝑖 ] = 𝑅𝐷𝐷 + 𝑅𝐷𝐼 × 𝑁 , which will always be
smaller than 𝑅𝐷𝐶𝑜𝑚𝑝 = 𝑅𝐷𝐷 + 𝑅𝐷𝐼 as long as 𝑅𝐷𝐼 and 𝑅𝐷𝐷 have the same sign, as
would typically be the case. When network sizes are constant with 𝑛𝑘 = 𝑛 for all 𝑘,
1

𝑅𝐷𝑂𝑣𝑒𝑟𝑎𝑙𝑙 = 𝑅𝐷𝐷 + 𝑅𝐷𝐼 × 𝑛. When the sign differs, the overall effect will be smaller
than the composite only in certain cases. For example, if the average network size is
3, 𝑅𝐷𝐼 = 1, and 𝑅𝐷𝐷 = −3, then 𝑅𝐷𝐶𝑜𝑚𝑝 = −2, which is smaller than 𝑅𝐷𝑂𝑣𝑒𝑟𝑎𝑙𝑙 =
−2.67. It is typically not expected for individual and disseminated effects to be in
opposite directions, but it is technically possible. Because the overall effect depends
on spurious features of the study design, including the size of the networks and the
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number of index members, it will not be generalizable from one study to the next or
to any scaled-up population, unless these features remain constant.
When there is no disseminated effect, the overall will always be less than or
equal to the composite. We also show that the overall effect will equal the composite
only when the individual effect is null, a rather unlikely occurrence in our
motivational setting. In Web Appendix 1, we also show properties for the
relationship between the overall and composite risk ratio.
Web Appendix 2 illustrates these relationships through some numerical
studies motivated by HPTN 037. If the individual and disseminated effects are in the
same direction, the magnitude of the overall effect decreases as the network size
increases. In the extreme, when there is no disseminated effect, the overall effect
will approach the null as the network size increases, while the composite effect
remains constant.
Estimation and Inference for Individual and Disseminated Effects
In network-randomized trials, the overall effect estimate has an immediate
causal interpretation. In contrast, index status is not randomized. The indexes are
recruited and then the remaining network members are recruited by the index.
Hence, the individual, disseminated, and composite effects only have a causal
interpretation when the estimator is fully adjusted for confounding.
Generalized estimating equations (GEEs) (17) with a log link and working
binomial variance can be used to estimate relative risks or rates, and an identity link
and working binomial variance can be used to estimate risk or rate differences, and
their confidence intervals adjusted for confounding (18, 19). These models also
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adjust the estimated parameter variances for correlation within networks and, if the
data are longitudinal, across visits within a participant. For log and identity links as
employed in this paper, the conditional and marginal model parameters of interest
are equivalent because the conditional mean is additive for the fixed and random
effects; thus, the estimated effects can be interpreted as either participant-level
and/or population-level estimates (20).
One way to estimate these parameters is using an aggregate model.
Assuming that the effects of the covariates 𝒁𝑘𝑖 are not modified by index status 𝑅𝑘𝑖
and the linear model with the identity link fits the data, let
𝐸[𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 , 𝑋𝑘 , 𝒁𝑘𝑖 ] = 𝛾0 + 𝛾1 𝑅𝑘𝑖 + 𝛾2 𝑋𝑘 + 𝛾3 𝑋𝑘 𝑅𝑘𝑖 + 𝛾4 𝒁𝑘𝑖 .
It follows that the effect of being an index member in a control network is
𝐸[𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 1, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ] − 𝐸[𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ] = 𝛾1 . In a network
randomized trial, there could be residual confounding even after adjusting for
covariates 𝒁𝑘𝑖 , so subtracting off these terms accounts for possible unmeasured
confounding due to self-selection of index status when estimating individual and
composite effects (21, 22). Thus, the individual rate difference (RD) can be
estimated by
̂ 𝑎𝐼 = 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 1, 𝑋𝑘 = 1, 𝒁𝑘𝑖 ] − 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 1, 𝒁𝑘𝑖 ]
𝑅𝐷
−{𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 1, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ] − 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ]}
= 𝛾̂0 + 𝛾̂1 + 𝛾̂2 + 𝛾̂3 + 𝛾̂4 𝒁𝑘𝑖 − (𝛾̂0 + 𝛾̂2 + 𝛾̂4 𝒁𝑘𝑖 ) − 𝛾̂1 = 𝛾̂3 .
When estimating the disseminated effect, only information from non-index network
members is included, therefore residual confounding of 𝑅𝑘𝑖 is not a concern.
Adjustment for observed baseline covariates 𝒁𝑘𝑖 is needed because randomization
Network-Randomized Studies with Dissemination
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in the full study sample does not necessarily guarantee exchangeability of 𝑋𝑘 within
subgroups of participants. The disseminated RD can be estimated by
̂ 𝑎𝐷 = 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 1, 𝒁𝑘𝑖 ] − 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ]
𝑅𝐷
= 𝛾̂0 + 𝛾̂2 + 𝛾̂4 𝒁𝑘𝑖 − (𝛾̂0 + 𝛾̂4 𝒁𝑘𝑖 ) = 𝛾̂2 .
Similarly, the composite RD can be estimated by
̂ 𝑎𝐶𝑜𝑚𝑝 = 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 1, 𝑋𝑘 = 1, 𝒁𝑘𝑖 ] − 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ]
𝑅𝐷
−{𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 1, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ] − 𝐸̂ [𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 = 0, 𝑋𝑘 = 0, 𝒁𝑘𝑖 ]}
= 𝛾̂0 + 𝛾̂1 + 𝛾̂2 + 𝛾̂3 + 𝛾̂4 𝒁𝑘𝑖 − (𝛾̂0 + 𝛾̂4 𝒁𝑘𝑖 ) − 𝛾̂1 = 𝛾̂2 + 𝛾̂3 .
Alternatively, if the effects of covariates 𝒁𝑘𝑖 differ by index status 𝑅𝑘𝑖 , a stratified
model could be used (Web Appendix 3). The estimators of the risk or rate ratio of
the three effects of interest are defined analogously and can be estimated using a
GEE with a log link and a working binomial variance. SAS code provided in Web
Appendix 4 demonstrates how to obtain these estimates and their corresponding
variances. Analyses were performed using SAS Version 9.4 (Cary, NC).
Illustrative Example
The HPTN 037 study (23) was a Phase III randomized controlled HIV preventive
intervention trial among people who inject drugs in the United States and Thailand
(13). Following a network-randomized design, the index participants were eligible if
they reported injecting drugs at least 12 times in the last three months, while the
network members had to have injected drugs or had sex with the index member
within the last three months. This study assessed the efficacy of a network-oriented
peer education intervention to promote HIV risk reduction behaviors among people
who inject drugs. Participants were followed for up to 30 months with visits
Network-Randomized Studies with Dissemination
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biannually with a median follow-up time of 18 months (Quartile 1 = 6, Quartile 3 =
24) to obtain information on HIV incidence and risk behaviors. The study was
underpowered for the primary outcome HIV incidence, so this analysis focused on
the occurrence of reported HIV risk behaviors. Two sites participated, Chiang Mai,
Thailand and Philadelphia, Pennsylvania, USA. At the time of this study, there was a
“war on drugs” in Thailand, which may have reduced trust among people who inject
drugs, possibly making the intervention less effective. Therefore, following the
recommendation of the study investigators (Carl Latkin, Johns Hopkins Bloomberg
School of Public Health, personal communication, 2016), this analysis only included
participants at the Philadelphia site. Index participants whose network was
randomized to the intervention arm received an educational intervention at
baseline and education boosters at six and 12 months. Participants in both the
intervention and control arms received HIV counseling and testing at each study
visit. The primary analysis for this trial reported the overall effect estimated by a
two-level GEE that accounted for correlations between participants within a
network and between visits within participants (13).
Shared cotton, an indicator for sharing needle/syringe “works”, was selected
as an outcome because it nicely exemplified our methods. A more comprehensive
clinical outcome, any injection-related risk behavior, included the following: sharing
injection equipment (needles, cookers, cotton, and rinse water), front and back
loading (i.e., injecting drugs from one syringe to another), injected with people not
well known or in shooting gallery, and not properly disinfecting injection
equipment. Following the original analysis of this study, these outcomes were
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assessed among participants who reported injection drug use in the last six months
at baseline. Statistical tests comparing prevalence of risk behaviors at baseline
between network and index members were performed using a GEE model that
accounted for within-network correlation.
First, the cumulative incidence of ever reporting the outcome by 30 months
of follow-up was analyzed using GEEs to account for correlations within networks,
using the robust sandwich estimator with a working exchangeable correlation
matrix (24, 25). Next, the longitudinal data were used to assess the effects of the
intervention on the inter-visit incidence rates of sharing “works” and of any
injection-related risk behavior using a multilevel GEE model. For estimation of the
individual and disseminated effects, these models were adjusted for baseline
covariates that were known or suspected risk factors for the outcome. For a few
outcomes, the models did not converge and log-Poisson models, which provide
consistent but not fully efficient estimates of the relative risk, were used (26, 27). All
statistical tests performed were two sided.
RESULTS
At the Philadelphia site of the HPTN 037 trial, there were 696 participants
and 560 participants had at least one follow-up visit with a total of 1,598 person
visits. At this site, 336 (48%) participants were in intervention networks (Table 2).
At baseline, participants in intervention networks had a comparable prevalence of
reported injection drug risk behavior (84%) compared to those in control networks
(86%); however, index participants reported more risk behaviors at baseline (89%)
as compared to network members (84%, P = 0.07).
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Table 3 presents the cumulative incidence of the risk behavior sharing
“works” and any report of injection-related risk behavior. Table 4 presents the
results for the effects of the intervention on each outcome. For both outcomes, there
was no evidence that the stratified model fit better than the aggregate model on
either scale based on an informal comparison of the log likelihoods. Tables 5 and 6
display the results of six-month inter-visit incidence rate differences and ratios for
sharing “works” and any report of injection-related risk behavior from the
longitudinal data. Based on an informal comparison of the log likelihoods, the
stratified model was a better fit than the aggregate model on the ratio scale for both
outcomes and on the difference scale for the any report outcome only.
There was a significant 40% overall reduction on the ratio scale (95%
confidence interval (CI): 8%, 61%) for the risk of ever sharing “works” by 30 months
(Table 4). In contrast, there was a substantially larger, significant 61% reduction on
the ratio scale in the adjusted composite risk of ever sharing “works” due to the
intervention (95% CI: 22%, 80%). The individual effect was nearly twice as large as
the disseminated effect, Risk Ratio (RR) = 0.52 vs. RR = 0.76, respectively.
In the longitudinal data, the overall intervention effect was significantly
protective with a 44% rate reduction on the ratio scale (95% CI: 11%, 65%) for
sharing “works” (Table 5). Based upon the adjusted stratified models, there was a
significant protective effect observed among network members with a 41% rate
reduction on the ratio scale (95% CI = 3%, 64%), and a somewhat greater 59%
individual rate reduction (95% CI = -6%, 84%). A significant 76% composite
adjusted rate reduction on the ratio scale was observed (95% CI = 45%, 89%).
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For the risk of ever any report of risk behavior by 30 months, there was a
near null individual effect, while the disseminated effect showed some suggestion of
protection (Table 4). In the adjusted aggregate models, there was a non-statistically
significant 17% reduction on the ratio scale in the composite risk of any report due
to the intervention (95% CI = -10%, 38%) and a comparable overall risk reduction.
The longitudinal analysis of the any injection-related risk behavior outcome
demonstrated a statistically significant protective overall effect with a 28% rate
reduction on the ratio scale (95% CI: 10%, 43%) (Table 6). Based on the adjusted
stratified models, the intervention provided a 29% rate reduction on the ratio scale
among network members (95% CI = 7%, 46%), but the individual effect did not
achieve statistical significance (RR = 0.92, 95% CI = 0.60, 1.40). A significant 35%
adjusted composite rate reduction on the ratio scale for any behavior was observed
(95% CI = 10%, 53%). As a sensitivity analysis, we used a compound symmetric
correlation matrix within a network between subjects and a first order
autoregressive correlation matrix within subject over time and the results were
comparable to those reported in Tables 5 and 6.
DISCUSSION
We developed estimators for individual and disseminated effects in networkrandomized trials. Because networks were randomized to the intervention, the
overall effect estimate has a causal interpretation. However, the overall effect is
influenced by ancillary factors, such as the size of the networks, and will typically
underestimate the composite effect (See Web Appendices 1 and 2). When there is no
unmeasured confounding and the model is correctly specified, individual and

Network-Randomized Studies with Dissemination

16

disseminated effect estimates also have causal interpretations and provide a more
in-depth understanding of the intervention’s impact.
In the HPTN trial, the overall effect of the intervention was statistically
significant with an estimated 28% risk reduction of any injection-related risk
behavior; however, although there was evidence for a significant 29% disseminated
risk reduction, the individual effect did not achieve statistical significance for that
same outcome. The original investigators reported only the overall effects (13),
which we found were slightly to moderately attenuated compared to the composite
effects that reveal the full power of the intervention. Somewhat surprisingly, the
disseminated effect was stronger than the individual effect for the report of any
injection-related risk behavior, suggesting that this intervention has substantial
resonance within the network beyond the effect of directly receiving the
intervention. Without consideration of dissemination, efforts to understand the full
array of mechanisms by which the intervention achieved its goal would be likely
overlooked.
The assumption of no unmeasured covariates associated with the treatment
and outcome (or with the index status and outcome) cannot be empirically verified.
For example, in HPTN 037, an individual’s unmeasured communication skills may
affect whether or not they come forward to be an index and this may lead to
unmeasured differences between index and non-index members. Future work could
involve extensions to address unmeasured confounding when evaluating
disseminated effects. In addition, the methods for incidence rate measures assume
that there is no bias due to dependent loss-to-follow-up, and in the longitudinal
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analysis, the missing visit process is ignorable (i.e., missing a visit is independent of
the outcome conditional on intervention status and observed baseline covariates). If
this assumption is questionable, censoring weights could be employed in the
analysis (28, 29). These methods assume no dissemination between networks,
although, it is possible in some settings that some network members will be in the
risk networks of more than one index member. In HPTN 037, indexes may interact
with participants outside their observed risk network because they may frequent
the same neighborhoods and venues. These methods could thus be extended to
accommodate dissemination between as well as within networks. In the HPTN trial,
effect modification was observed for sex and participation in a drug treatment
program. Future work could entail estimation of these within-strata effects and an
application of such methods as g-estimation to ascertain population-level effects
(30).
These methods could also be extended to correct for bias due to
misclassification or measurement error in the self-reported outcome or covariates
(31). We assume that the reported effect estimates are not subject to social
desirability effects, which could vary by intervention arm over time and
dissemination may reinforce this. Furthermore, the indexes may have
underreported risk connections or study investigators may have missed some
networks entirely. More accurate ways to elicit and recruit network member
nominations and contact information could be developed and methods to infer
unobserved or misclassified risk and social connections could be improved.
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A network-based program implementation can be offered at a reduced cost,
because only a subset of participants needs to receive the intervention. The example
highlights the need for methods to adequately power trials to assess individual and
disseminated effects. Future work could include evaluating the disseminated effects
of treatment as prevention and similar interventions in HIV trials, including
extensions for networks with more than one index participant (32-36). Extension of
these methods to estimate both individual and disseminated effects of the
components of multifaceted interventions is needed for future complex HIV/AIDS
implementation science research, particularly that engaging drug-using or sexual
risk networks.
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Figure 1. Schematic diagram of the subsets of data used for each estimator
(individual, disseminated, composite and overall) based on a format provided in (5)
Composite Effect
Disseminated Effect

Network
Members

Individual Effect

Network
Members

Index

Control Network

Index

Intervention Network

Overall Effect
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Table 1. Related Terminology for Estimation of Individual and Disseminated Effects
Recommended
Term
Individual

Disseminated

Composite

Overallf

Alternative Terms

Definition

Direct

Effect on those directly receiving
intervention beyond being in an
intervention network

Indirect, Social Diffusion,
Diffusion of Innovation,
Contamination, Spillover

Effect on those who received
intervention indirectly through the
index participant

Total

Combined individual and
disseminated effects; Effect among
indexes in intervention networks
contrasted with effect among
network members in control
networks
Effect among members of
intervention networks contrasted
with effect among members of
control networks

Crude

Parameter of Interest

𝑐

Network-Randomized
Design Estimators
Aggregatea
Stratifiedb
𝑑

𝐸[𝑌𝑘𝑖𝑗 (1,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,1)]

𝐸[𝑌𝑘𝑖𝑗 (0,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,0)]𝑒

𝐸[𝑌𝑘𝑖𝑗 (1,1)] − 𝐸[𝑌𝑘𝑖𝑗 (0,0)]

𝑔

ℎ

𝐸[𝑌𝑘𝑖𝑗 (∙, 1)] − 𝐸[𝑌𝑘𝑖𝑗 (∙, 0)]

𝛾̂3

𝛼̂1 − 𝛽̂1

𝛾̂2

𝛽̂1

𝛾̂2 + 𝛾̂3

𝛼̂1

𝛽̂1∗

a

For a network-randomized design, rate difference parameters of the individual, disseminated, and composite effects, respectively, are estimated
from an aggregate GEE model with an identity link and binomial variance:
𝐸[𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 , 𝑋𝑘 , 𝒁𝑘𝑖 ] = 𝛾0 + 𝛾1 𝑅𝑘𝑖 + 𝛾2 𝑋𝑘 + 𝛾3 𝑋𝑘 𝑅𝑘𝑖 + 𝛾4 𝒁𝑘𝑖
b
For a network-randomized design, rate difference parameters of the individual, disseminated, and composite effects, respectively, are estimated
from a stratified GEE model with an identity link and binomial variance:
𝐸[𝑌𝑘𝑖𝑗 |𝑅𝑘𝑖 , 𝑋𝑘 , 𝒁𝑘𝑖 ] = 𝐼(𝑅𝑘𝑖 = 0) × (𝛽0 + 𝛽1 𝑋𝑘 + 𝛽2 𝒁𝑘𝑖 ) + 𝐼(𝑅𝑘𝑖 = 1) × (𝛼0 + 𝛼1 𝑋𝑘 + 𝛼2 𝒁𝑘𝑖 )
c
(1,1)
𝑌𝑘𝑖𝑗
is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was an index member in a
network randomized to the intervention. 𝐸[𝑋] is the expectation of the random variable 𝑋.
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𝑌𝑘𝑖𝑗 (0,1) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was a network member in a
network randomized to the intervention.
e
𝑌𝑘𝑖𝑗 (0,0) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was a network member in a
network randomized to the control.
f
For network-randomized design, parameter of the overall effect is estimated from a GEE model with an identity link and binomial variance:
𝐸[𝑌𝑘𝑖𝑗 |𝑋𝑘 ] = 𝛽0∗ + 𝛽1∗ 𝑋𝑘
g
𝑌𝑘𝑖𝑗 (⋅ ,1) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was in a network randomized
to the intervention.
h
𝑌𝑘𝑖𝑗 (⋅ ,0) is the potential outcome of participant 𝑖 at visit 𝑗 in network 𝑘, if possibly contrary to fact, this participant was in a network randomized
to the control.
d
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Table 2 Baseline characteristics of the HPTN 037 study population, Philadelphia
site, 2002-2006, by treatment group (n = 696)

Characteristics
Network Member Role
Index
Network member
Network sizeb
Male
Age (years)b
Drug treatment programb
Housingc
Spent night on street, car, park or abandoned
building
Spent time in jail
Sexual riskd
More than one sex partner
Unprotected sex in the last week
Unprotected sex with non-primary
Partner
Injection drug behaviorse
Injection drug use in the last 6 month
Injection drug use in the last month
Heroin
Heroin w/ Cocaine
Heroin w/ Amphetamine
Cocaine
Amphetamine
Number of days injected in the last month
0-5
6-14
15-29
Everyday
Injection risk behaviors in the last monthf
Shared rinse water
Shared cooker
Shared cotton
Used front or back loaded syringe
Injected with an unclean syringe
Passed a syringe to someone else
Used a syringe after someone else
Injected with someone you don’t know

Network Randomizationa
Intervention
Control
% of (n = 336) % of (n = 360)
33
67
3 (1.27)
68
41 (10)
22

33
67
3 (1.04)
69
40 (10)
32

25

24

19

15

42
50
16

40
50
19

93
99
94
42
1
37
2

94
97
96
35
1
37
2

9
8
24
59

9
9
16
65

44
57
41
21
13
48
37
19

51
62
46
23
15
53
39
22
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well
Injected in a shooting gallery
Did not clean syringe after use

61
14

56
13

There were 112 intervention networks and 120 control networks. Values of polytomous
variables may not sum to 100% due to rounding.
b Values are expressed as mean (standard deviation).
c In past 6 months.
d In last month.
e Injection drug behaviors reported only for participants reporting injection drug use in the
past 6 months.
f Injection risk behaviors reported only for participants reporting injection drug use in the
last month.
a
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Table 3. Risk of ever reporting injection-related risk behavior by 30 months after baseline with
95% confidence intervals (CI) at the HPTN 037 Philadelphia site, 2002-2006 (n = 651)
Index Participants
Network
Randomization

Network Participants

Total
Person

Shared
“Works”
Reported

30-month
Cumulative
Incidence,
%

Total
Person

Shared
“Works”
Reported

30-month
Cumulative
Incidence,
%

Treatment

112

10

9

202

28

14

Control

120

24

20

217

42

19

Combined Control

337

66

20

Treatment

112

48

43

202

75

37

Control

120

58

48

217

97

45

Combined Control

337

155

46

Any shared works

Any risk behavior
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Table 4. Effects of the intervention on the risk of ever reporting injection-related risk behavior by 30 months after baseline with 95%
confidence intervals (CI) at the HPTN 037 Philadelphia site, 2002-2006 (n = 651)
Aggregate Models

Stratified Models
Unadjusted
Effect

Adjusteda

Unadjusted

Adjusteda

Unadjusted

Adjusteda

Unadjusted

Adjusteda

RD

95% CI

RD

95% CI

RR

95% CI

RR

95% CI

RD

95% CI

RD

95% CI

RR

95% CI

RR

95% CI

Individual

−5

−16, 7

−7

−20, 5

0.65

0.28, 1.51

0.47

0.18, 1.21

−5

−16, 6

−8

−19, 3

0.65

0.28, 1.47

0.52

0.23, 1.15

Disseminated

−6

−14, 1

−5

−13, 2

0.69

0.42, 1.13

0.75

0.45, 1.25

−6

−14, 1

−5

−13, 3

0.69

0.42, 1.14

0.76

0.46, 1.25

Composite

−11

−20, −2

−13

−22, −3

0.45

0.22, 0.89

0.35

0.16, 0.78

−11

−20, −2

−13

−22, −4

0.45

0.22, 0.89

0.39

0.20, 0.78

Overall

−8

−14, −2

−8

−14, −2

0.60

0.39, 0.92

0.61

0.39, 0.94

−8

−14, −2

−8

−14, −2

0.60

0.39, 0.92

0.61

0.39, 0.94

Individual

2

−14, 18

0

−18, 17

1.07

0.73, 1.56

0.99

0.68, 1.45

2

−13, 18

0

−16, 15

1.07

0.76, 1.53

0.97

0.68, 1.39

Disseminated

−8

−18, 2

−5

−16, 5

0.83

0.64, 1.07

0.88

0.69, 1.13

−8

−18, 2

−7

−17, 4

0.83

0.64, 1.06

0.85

0.66, 1.10

Composite

−5

−18, 7

−6

−20, 8

0.89

0.67, 1.18

0.88

0.66, 1.16

−5

−18, 7

−7

−20, 6

0.89

0.67, 1.18

0.83

0.62, 1.10

Overall

−7

−15, 1

−7

−16, 2

0.85

0.69, 1.04

0.85

0.69, 1.04

−7

−15, 1

−7

−16, 2

0.85

0.69, 1.04

0.85

0.69, 1.04

Any shared works

Any risk behaviorb

CI = Confidence Interval; RD = Risk Difference per 100 persons; RR = Risk Ratio.
Adjusted for sex (male vs. female), age (years), marital status (single vs. not single), education (at least high school vs. not), and employment (unemployed vs.
employed), and time-varying covariates set to their baseline value: crack use (yes vs. no), cocaine use (yes vs. no), benzodiazepines (yes vs. no), heroin (yes vs.
no), drug treatment program (yes vs. no), spent the night on the street (yes vs. no), spent time in jail (yes vs. no), alcohol use (got drunk vs. not), injected heroin
(yes vs. no), heroin and cocaine (yes vs. no), injected cocaine (yes vs. no), and number of days injected in the last month (0-5 days, 6-14 days, 15-29 days vs.
everyday).
b
On the ratio scale, the model excluded number of days injected variable because of model convergence issues. Models for the overall effect also excluded
injected cocaine. Stratified model for individual, disseminated, and composite effects also excluded spent time in jail, heroin use, and injected cocaine.
a
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Table 5. Six-month inter-visit incidence rate ratios and rate differences for the effect of the HPTN 037 randomized intervention on the rate of sharing
“works” risk behavior during follow-up with 95% confidence intervals (CI) among participants with at least one follow-up visit at the Philadelphia site,
2002-2006
Unadjusted
RR

95% CI

RD

Baseline Adjusteda,b
95% CI

RR

95% CI

RD

95% CI

Stratified Models
Overallc

0.56

0.35, 0.89

-0.05

-0.10, -0.01

0.52

0.32, 0.83

-0.06

-0.11, -0.01

Individuald

0.58

0.23, 1.48

-0.05

-0.14, 0.04

0.41

0.16, 1.06

-0.08

-0.18, 0.01

Disseminatede

0.66

0.38, 1.12

-0.04

-0.09, 0.02

0.59

0.36, 0.97

-0.04

-0.09, 0.02

Compositef

0.38

0.18, 0.81

-0.09

-0.16, -0.02

0.24

0.11, 0.55

-0.12

-0.19, -0.05

Aggregate Models
Overall

0.56

0.35, 0.89

-0.05

-0.10, -0.01

0.52

0.32, 0.83

-0.06

-0.11, -0.01

Individual

0.56

0.25, 1.26

-0.06

-0.13, 0.02

0.55

0.25, 1.19

-0.08

-0.15, 0.00

Disseminated

0.69

0.04, 1.17

-0.03

-0.09, 0.02

0.64

0.38, 1.08

-0.03

-0.09, 0.02

Composite

0.39

0.18, 0.81

-0.09

-0.16, -0.02

0.35

0.17, 0.73

-0.11

-0.18, -0.04

CI = Confidence Interval; RD = Risk Difference per 100 person-visits; RR = Risk Ratio.
a Adjusted

for sex (male vs. female), age (years), marital status (single vs. not single), education (at least high school vs. not), and
employment (unemployed vs. employed), and time-varying covariates set to their baseline value: crack use (yes vs. no), cocaine use (yes
vs. no), benzodiazepines (yes vs. no), smoked heroin (yes vs. no), drug treatment program (yes vs. no), spent the night on the street (yes
vs. no), spent time in jail (yes vs. no), alcohol use (got drunk vs. not), injected heroin (yes vs. no), heroin and cocaine (yes vs. no), injected
cocaine (yes vs. no), and number of days injected in the last month (0-5 days, 6-14 days, 15-29 days vs. everyday).
b One participant missing information on spent the night on the street and spent time in jail at baseline.
c There were 174 events, 1,598 person-visits and 560 people included.
d There were 58 events, 782 person-visits and 270 people included.
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There were 158 events, 1,319 person-visits and 463 people included.
There were 132 events, 1,095 person-visits and 387 people included.
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Table 6. Six-month inter-visit incidence rate ratios and rate differences for the effect of the HPTN 037 randomized intervention on the rate of any
injection-related risk behavior during follow-up with 95% confidence intervals (CI) among participants with at least one follow-up visit at the
Philadelphia site, 2002-2006
Unadjusted
RR

95% CI

Baseline Adjusteda,b

RD

95% CI

RR

95% CI

RD

95% CI

Stratified Models
Overallc

0.72

0.57, 0.90

-0.09

-0.16, -0.02

0.69

0.56, 0.86

-0.09

-0.16, -0.03

Individuald

0.97

0.64, 1.48

-0.02

-0.15, 0.12

0.92

0.60, 1.40

-0.06

-0.19, 0.07

Disseminatede

0.73

0.55, 0.97

-0.09

-0.17, 0.00

0.71

0.54, 0.93

-0.08

-0.16, -0.01

Compositef

0.71

0.52, 0.97

-0.10

-0.21, 0.00

0.65

0.47, 0.90

-0.14

-0.24, -0.03

Aggregate Models
Overall

0.72

0.57, 0.90

-0.09

-0.16, -0.02

0.69

0.56, 0.86

-0.09

-0.16, -0.03

Individual

0.96

0.67, 1.39

-0.02

-0.14, 0.10

0.91

0.62, 1.33

-0.05

-0.17, 0.07

Disseminated

0.75

0.57, 0.98

-0.08

-0.16, 0.00

0.72

0.55, 0.94

-0.08

-0.16, 0.01

Composite

0.72

0.53, 0.98

-0.10

-0.21, 0.01

0.65

0.47, 0.90

-0.13

-0.23, -0.02

CI = Confidence Interval; RD = Risk Difference per 100 person-visits; RR = Risk Ratio.
a Adjusted for sex (male vs. female), age (years), marital status (single vs. not single), education (at least high school vs. not), and employment
(unemployed vs. employed), and time-varying covariates set to their baseline value: crack use (yes vs. no), cocaine use (yes vs. no), benzodiazepines
(yes vs. no), smoked heroin (yes vs. no), drug treatment program (yes vs. no), spent the night on the street (yes vs. no), spent time in jail (yes vs. no),
alcohol use (got drunk vs. not), injected heroin (yes vs. no), heroin and cocaine (yes vs. no), injected cocaine (yes vs. no), and number of days injected in
the last month (0-5 days, 6-14 days, 15-29 days vs. everyday).
b One participant missing information on spent the night on the street and spent time in jail at baseline.
c
d

There were 509 events, 1,598 person-visits and 560 people included.
There were 204 events, 782 person-visits and 270 people included.
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There were 433 events, 1,319 person-visits and 463 people included.
There were 381 events, 1,095 person-visits and 387 people included.
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